Cardiac Hippo/YAP gene therapy program
undiscloseddrug program · high · Wed Apr 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Promote cardiac regeneration and cardiomyocyte renewal after myocardial infarction or heart failure by modulating Hippo/YAP signaling.
AAV genetic medicine approach intended to knock down or modulate Hippo signaling and activate innate regenerative pathways; public record includes a ClinicalTrials.gov study assessing left ventricular administration.
ClinicalTrials.gov record NCT06831825 was published on 2025-04-23 for a study assessing left ventricular administration.
Preclinical publications report reversal of systolic heart failure after infarction, cardiomyocyte renewal in pigs after myocardial infarction, and resolution of arrhythmic events in pigs after myocardial infarction.